Dianthus Therapeutics Inc
DNTH - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.61B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $4.61 Billion |
|---|---|
| Enterprise Value | $4.50 Billion |
| Earnings per Share | $-4.2 |
| Beta | 0.08 |
| Outstanding Shares | 56,029,124 |
Return
| Return on Equity | -2.55% |
|---|---|
| Return on Assets | -2.47% |
| Return on Invested Capital | -17.53% |
Valuation & Multiples
| P/E Ratio | -633.69 |
|---|---|
| PEG | -1078.4 |
| Price to Sales | - |
| Price to Book Ratio | 4.15 |
| Enterprise Value to Revenue | 3122.93 |
| Enterprise Value to EBIT | -21.77 |
| Enterprise Value to Net Income | -151 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 5, 2026
EPS Estimate
$-0.94
Consensus analyst estimateRevenue Estimate
$460,928
Consensus analyst estimateNext Earnings Call
Expected Date
March 8, 2027
EPS Estimate
$-1.06
Consensus analyst estimateRevenue Estimate
$411,312
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 93.27% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.71%▼ 135.94% |
|---|---|
| Total Invested | $84.60M▼ 98.69% |
| Investors Holding | 40▼ 239.00% |
About Dianthus Therapeutics Inc
81 employees
CEO: Jason Gardner
magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of trans...